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METHODOLOGY Open Access
In vivo measurement of apolipoprotein E from
the brain interstitial fluid using microdialysis
Jason D Ulrich1,2,4, Jack M Burchett1,2,4, Jessica L Restivo1,2,4, Dorothy R Schuler1,2,4, Philip B Verghese1,2,4,
Thomas E Mahan1,2,4, Gary E Landreth5, Joseph M Castellano1,2,4, Hong Jiang1,2,4, John R Cirrito1,2,4
and David M Holtzman1,2,3,4*
Abstract
Background: The APOE4 allele variant is the strongest known genetic risk factor for developing late-onset
Alzheimer’s disease. The link between apolipoprotein E (apoE) and Alzheimer’s disease is likely due in large part to
the impact of apoE on the metabolism of amyloid β (Aβ) within the brain. Manipulation of apoE levels and
lipidation within the brain has been proposed as a therapeutic target for the treatment of Alzheimer’s disease.
However, we know little about the dynamic regulation of apoE levels and lipidation within the central nervous
system. We have developed an assay to measure apoE levels in the brain interstitial fluid of awake and freely
moving mice using large molecular weight cut-off microdialysis probes.
Results: We were able to recover apoE using microdialysis from human cerebrospinal fluid (CSF) in vitro and mouse
brain parenchyma in vivo. Microdialysis probes were inserted into the hippocampus of wild-type mice and
interstitial fluid was collected for 36 hours. Levels of apoE within the microdialysis samples were determined by
ELISA. The levels of apoE were found to be relatively stable over 36 hours. No apoE was detected in microdialysis
samples from apoE KO mice. Administration of the RXR agonist bexarotene increased ISF apoE levels while ISF Aβ
levels were decreased. Extrapolation to zero-flow analysis allowed us to determine the absolute recoverable
concentration of apoE3 in the brain ISF of apoE3 KI mice. Furthermore, analysis of microdialysis samples by
non-denaturing gel electrophoresis determined lipidated apoE particles in microdialysis samples were consistent in
size with apoE particles from CSF. Finally, we found that the concentration of apoE in the brain ISF was dependent
upon apoE isoform in human apoE KI mice, following the pattern apoE2>apoE3>apoE4.
Conclusions: We are able to collect lipidated apoE from the brain of awake and freely moving mice and monitor
apoE levels over the course of several hours from a single mouse. Our technique enables assessment of brain apoE
dynamics under physiological and pathophysiological conditions and in response to therapeutic interventions
designed to affect apoE levels and lipidation within the brain.
Keywords: Microdialysis, Apolipoprotein E, Alzheimer’s disease
Background
Intercellular lipid transport in the central nervous sys-
tem (CNS) is predominantly mediated by high-density
lipoprotein (HDL)-like particles containing the lipid-
binding protein apolipoprotein E (apoE) [1]. Within the
CNS, apoE is secreted primarily by astrocytes [2]. In
humans there are three common APOE allele variants:
APOE2, APOE3, and APOE4. Possession of the ε4 allele
is the strongest known genetic risk factor for developing
late-onset Alzheimer’s disease (LOAD), while apoE2 is
protective[2]. ApoE likely influences AD in large part
through the isoform-dependent effects of apoE on the
metabolism of amyloid-β (Aβ) in the brain. ApoE
isoforms differentially influence the rate of Aβ clearance
from the brain with the order of clearance being
apoE4<apoE3<apoE2 [3]. ApoE also facilitates the for-
mation of Aβ aggregates (e.g. oligomers and fibrils)
within the brain, which are thought to induce synaptic
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and neuronal toxicity [4]. In addition to isoform-
dependent effects, the degree of apoE lipidation and
apoE concentration within the brain also influences Aβ
plaque deposition and Aβ clearance [5-8]. ApoE likely
plays additional roles in the brain in processes such as
synaptic plasticity, regulation of extracellular lipid me-
tabolism, and inflammation (for review, see [2]).
Despite the importance of apoE in AD, little is known
about the physiological regulation of apoE within the
CNS. To date, analysis of the regulation of apoE expres-
sion and lipidation within the CNS has been limited to
in vitro cell culture systems and assessment of apoE
from homogenized brain extracts or cerebral spinal fluid
(CSF). Thus, very little is known about the dynamic
regulation of apoE within the brain, particularly within
the interstitial fluid (ISF), where apoE is present immedi-
ately after secretion from astrocytes and where it likely
functionally interacts with Aβ and other molecules.
Given recent interest in apoE as a therapeutic target for
AD, there is a critical need to develop methods to dy-
namically assess the levels, lipidation, and effects of apoE
within the brain in vivo [8,9].
Microdialysis is a widely used and powerful technique
that has been employed to study neurotransmitters and
other small molecules or peptides within the brain [10].
In AD, microdialysis has been instrumental in studying
the dynamics of Aβ production and clearance in vivo
[3,11-14]. However, the comparatively large size of
lipidated apoE particles (~300 kDa) has impeded the
utility of microdialysis to similarly assess apoE metabo-
lism within the brain. A recent report demonstrated that
a high molecular weight cut-off (MWCO) microdialysis
probe was capable of collecting small (<30 kDa) proteins
from the brain ISF[15]. We hypothesized that such a
probe might be useful for collecting lipidated lipopro-
teins. Here, we report the use of the high MWCO
AtmosLM microdialysis probe to collect and quantify
lipidated apoE particles from the brain ISF of awake
and freely moving animals by in vivo microdialysis.
Non-denaturing gel electrophoresis analysis of the ISF
samples indicates that apoE-containing particles are
heterogeneous in size and are consistent in size with
apoE-containing particles from CSF. Using this tech-
nique, we found that the level of apoE in the hippocam-
pal ISF is dependent upon apoE isoform. The ability to
dynamically measure apoE levels and lipidation in the
brain ISF will be useful for studying lipid metabolism
within the brain ISF and the molecular basis for the ef-
fect of apoE on AD pathology.
Results and discussion
The relatively large hydrated diameter of lipidated apoE
particles prohibits collection by commonly used lower
MWCO microdialysis probes (typically 6-40 kDa). To
circumvent this issue, we optimized the use of a 1,000
kDa MWCO microdialysis probe for collection of apoE.
We first characterized the efficiency of apoE collection
from human CSF using microdialysis in vitro. The recov-
ery of analyte by microdialysis is inversely related to the
flow rate through the microdialysis probe[10]. By ex-
trapolating along the recovery curve to a zero flow rate,
it is possible to estimate the maximum amount of ex-
changeable analyte [10]. Microdialysis samples were col-
lected hourly at flow rates ranging from 0.4 μL/min to
1.6 μL/min. As expected, decreasing the flow rate in-
creased the amount of apoE detected in microdialysis
samples (Figure 1A). We estimated the total amount of
exchangeable apoE to be 111.2 ± 14.4 ng/mL, which rep-
resented ~2% of the 6024 ± 152.3 ng/mL total apoE
detected within the CSF samples.
Having determined it was possible to collect apoE by
microdialysis using a 1,000 kDa MWCO probe, we next
tested whether we could collect apoE in vivo. We im-
planted microdialysis probes into the hippocampus of 3-
4 month old wild-type mice and collected microdialysis
samples every two hours at a constant flow rate of 1.0 μL/
min. Under these conditions, levels of apoE within the
hippocampal ISF were stable throughout the 36 hour col-
lection duration (Figure 1B). Similar to previous studies,
we observed only minimal astrogliosis in the cortex prox-
imal to the site of cannula insertion and no evidence of
substantial inflammation following microdialysis (data not
shown)[14,16]. We found the mean concentration of re-
coverable apoE in the hippocampal ISF to be 10.1 ± 1.8
ng/mL at a constant flow rate of 1.0 μL/min (Figure 1C).
To verify the specificity of our assay we also performed
microdialysis in apoE KO mice. As expected, we detected
no apoE in the apoE KO mouse ISF dialysate (Figure 1C).
These data confirm that we are able to collect apoE from
the brain ISF and specifically measure how it changes over
the course of several hours in a single mouse.
Due to the relatively high variance we observed in apoE
levels, we performed a power analysis to determine if we
could feasibly detect statistically significant differences in
ISF apoE levels. Given the observed mean concentration
and average standard deviation of murine ISF apoE at a
given time point, we estimate ~5-6 animals per group
would be required to observe a statistically significant 70%
change in apoE levels at an α-value of 0.80 and p-value of
0.05. Furthermore, because in vivo microdialysis enables
assessment of changes in apoE levels in a single mouse,
normalizing the level of apoE detected to a baseline value
(i.e. the mean level from first 9 hours of collection) for
each animal eliminates inter-animal variability in apoE
levels and allows for detection of a statistically significant
50% change in relative apoE levels with ~5-6 animals.
Recent studies propose that modulating apoE levels
and lipidation in the brain using nuclear hormone
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receptor agonists may be an effective therapeutic target
for AD [8,17]. We tested whether we could detect
changes in ISF apoE and Aβ levels following administra-
tion of the retinoid-X-receptor (RXR) agonist bexarotene
using microdialysis. We monitored hippocampal ISF
apoE and Aβ levels in 2-month old APP/PS1 mice.
Following establishment of a 6-hour baseline apoE and
Aβ level, bexarotene (100 mg/kg) or vehicle (water) were
administered to the mice via oral gavage. Bexarotene
treatment led to a steady increase in ISF apoE levels be-
ginning ~12 hours post-administration (Figure 2A). ISF
apoE levels were increased 2.5-fold 30-36 hours post-
Figure 1 Analysis of apoE levels by microdialysis in vitro and in vivo. A. Microdialysis samples were collected hourly from human CSF
in vitro at flow rates ranging from 0.4 μL/min to 1.6 μL/min. The concentration of apoE within microdialysis samples and CSF was determined by
ELISA. Data points represent mean ± SEM (n=3). A single-phase exponential decay curve (r2=0.93) was used to calculate the estimated mean
concentration of apoE at zero flow. B. Microdialysis probes were implanted into the hippocampus of 3-4 month old mice and ISF collected bi-
hourly for 36 hours. The concentration of apoE within microdialysis samples was determined by ELISA. Data points represent mean ± SEM (n=5).
C. The mean concentration of murine apoE in ISF microdialysis samples from WT (n=5) and apoE KO mice (n=2) was determined by ELISA. ISF
samples were collected at a constant flow rate of 1.0 μL/min. Data are presented as mean ± SEM.
Figure 2 Bexarotene increases ISF apoE levels and decreases ISF Aβ levels. A. ISF Aβx-40 and apoE levels in the hippocampus of 2-month old
APP/PS1 mice were monitored using in vivo microdialysis. Following establishment of a 6 hour baseline ISF level for Aβx-40 and apoE, mice were
administered bexarotene (100 mg/kg p.o.) or vehicle (water) and ISF Aβx-40 and apoE levels assessed for an additional 36 hours. B. The mean percent
change from baseline of ISF apoE and Aβx-40 levels 30-36 post-administration was compared between vehicle and bexarotene treated mice. Bexarotene
significantly increased ISF apoE levels (247 ± 34.3%, n=2) compared to vehicle (103 ± 5.2%, n=3) (*p<0.05, unpaired t-test). Bexarotene decreased ISF Aβ
levels (65.1 ± 8.1%, n=3) compared to vehicle (100 ± 3.7%, n=6). (**p<0.005, unpaired t-test).
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treatment (Figure 2A and B). ISF Aβ levels were decreased
by ~35%, similar to previous observations (Figure 2A and
B) [8]. These data demonstrate the utility of microdialysis
to detect biologically relevant, pharmacologically-induced
changes in ISF apoE levels.
To further validate our technique we tested whether
we could determine an absolute concentration of recov-
erable apoE within the hippocampal ISF by the extrapo-
lated zero-flow method. We implanted microdialysis
probes into the hippocampus of 3-4 month old apoE3
KI mice and collected ISF dialysate at flow rates ranging
from 0.4 μL/min to 1.6 μL/min. We then fit a single-
exponential decay curve to the concentration of apoE as a
function of flow rate (Figure 3A). Our analysis determined
the concentration of recoverable apoE3 in the ISF under
steady-state conditions was 38.1 ± 4.0 ng/mL (n=4).
ApoE particles in the CSF or secreted by cultured as-
trocytes are a heterogeneous mixture that vary in size
depending upon the degree of lipidation [5,18-20]. We
compared the lipidation of apoE3 particles collected
from brain parenchymal ISF to apoE3 particles in CSF
by non-denaturing gel electrophoresis, which separates
proteins based upon their hydrated diameter. As previ-
ously reported, apoE3 particles in CSF were heteroge-
neous in size, ranging from 8.1 nm to 17.0 nm (Figure 2B)
[21]. ApoE3 particles collected from ISF were lipidated
and were similar in size to particles found in CSF (Fig-
ure 3B). We further verified that the lipidated apoE3 parti-
cles in ISF samples were not due to contamination from
the artificial cerebral spinal fluid (aCSF) used for microdi-
alysis (Figure 3B).
Previous studies found an isoform-dependent effect on
apoE levels in the hippocampus, cortex, and CSF in apoE
KI mice with apoE2-expressing mice having the highest
levels of apoE and apoE4 expressing mice the lowest
[22,23]. Therefore, we tested whether we could detect
isoform-dependent differences in apoE levels in the hippo-
campal ISF by microdialysis. We implanted microdialysis
probes into the hippocampus of 3-4 month old apoE2,
apoE3 or apoE4 KI mice and assessed the absolute concen-
tration of human apoE in the ISF dialysate by ELISA. The
concentration of apoE2 within the ISF (46.7 ± 15.6 ng/mL,
n=3) was significantly greater than that of apoE4 (12.6 ±
1.8 ng/mL, n=4) and the concentration of apoE3 (18.7 ±
5.3, n=6) was at a level between that of apoE2 and apoE4
(Figure 4A). To confirm that the observed differences were
not due to differential detection of apoE isoforms by the
antibodies used in the ELISA, we measured equal amounts
of recombinant apoE2, apoE3, and apoE4 by ELISA and
found no significant difference in detection among the
apoE isoforms (Figure 4B). Therefore, these results support
the utility of our assay for observing differences in apoE
levels in the ISF that are similar to those seen in CSF and
in the brain.
Conclusions
We have developed a sensitive microdialysis assay for
assessing the levels and lipidation of apoE within the
Figure 3 Analysis of hippocampal ISF apoE3 levels and lipidation. A. The apoE concentration in microdialysis samples collected at flow rates
ranging from 0.4 μL/min to 1.6 μL/min was determined by ELISA. Data are presented as mean ± SEM (n=4). A single-phase exponential decay
curve (r2=0.93) was used to calculate the estimated mean concentration of apoE3 at zero flow. B. The lipidation of apoE in ISF and CSF samples
was analyzed by non-denaturing gel electrophoresis using 4-20% Tris-glycine gradient gels. No apoE was detected in the aCSF used for
microdialysis. The samples were run on the same gel; however the CSF panel is from a shorter exposure than the ISF panel for clarity.
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brain parenchymal ISF in awake and freely moving ani-
mals. Despite being the strongest genetic risk factor for
developing late-onset AD, the precise molecular mecha-
nism by which APOE genotype influences the risk of de-
veloping AD remains unknown. Previous studies indicate
that apoE affects the metabolism and oligomerization of
Aβ within the brain [3,4,24] as well as influences a variety
of other biological processes [2]. Recent studies have
therapeutically targeted the levels and lipidation of apoE
to enhance clearance of Aβ from the brain [8]. The
method described here will be useful in sampling ISF apoE
levels over time in order to assess the relationship between
apoE levels and lipidation and Aβ metabolism in the brain.
Furthermore, assessment of apoE by microdialysis could
prove useful in investigating the regulation of extracellular
lipid homeostasis within the brain. This may be important
in synaptic plasticity and repair after brain injury, as well
as potentially play a role in neurodegenerative diseases
such as Niemann-Pick disease [25].
Methods
Materials
Mouse apoE monoclonal antibodies (mHJ 6.1, mHJ 6.2,
and mHJ 6.3) were generated in-house and have been
described previously [9]. Polyclonal apoE antibody
(50A-G1b) was purchased from Academy Bio-medical
Co. (Houston, TX, USA). Recombinant apoE3 was
purchased from Leinco Technologies (St. Louis, MO,
USA). Bexarotene (Targretin™) was provided by Dr.
Gary Landreth (Case Western Reserve University).
Animals
ApoE2, apoE3, and apoE4 knock-in (KI) mice were gen-
erously provided by Dr. Patrick M. Sullivan (Duke Uni-
versity) and have been previously described [26]. To
assess murine apoE, wild type mice on a mixed C57BL6/
C3H background were utilized (Jackson Labs). APPswe/
PS1δE9 mice (APP/PS1) and ApoE knock-out (KO) mice
were obtained from Jackson Labs. Mice were housed
under constant light/dark conditions and had access to
food and water ad libitum. All experimental protocols
were approved by the Animal Studies Committee at
Washington University in St. Louis.
In vitro microdialysis
Human CSF was collected by lumbar puncture from
cognitively normal research volunteers from the Wash-
ington University Memory and Aging Project [27]. 1,000
kDa MWCO membrane microdialysis probes (AtmosLM
Microdialysis probe, PEP-X-0Y, Eicom, San Diego, CA,
USA) were connected to a two-channel peristaltic push-
pull pump (MAB20, SciPro, Sanborn, NY, USA). The
inlet-port of the microdialysis probe was connected to
the push channel of the pump using Joint Teflon Tubing
(inner diameter 0.1 mm) (JT-10-100, Eicom, San Diego,
CA, USA) and the outlet-port was connected to the pull
channel of the pump using Teflon (FEP) tubing (inner
diameter 0.12 mm). The flow rates of the push and pull
channels were calibrated to within 5% tolerance. The
probes were then flushed with microdialysis perfusion
solution (4% human albumin (Gemini Bioproducts, West
Sacramento, CA, USA)-containing artificial CSF (aCSF)
(in mM: 1.3 CaCl2, 1.2 MgSO4, 3 KCl, 0.4 KH2PO4, 25
NaHCO3, 122 NaCl, pH 7.35) that had been prepared on
the day of use and filtered through a 0.1 μm PES
membrane. Microdialysis was performed at flow rates of
0.4 μL/min to 1.6 μL/min and samples were collected
hourly using a refrigerated fraction collector (Univentor
820 Microsampler, SciPro). Extrapolation from zero-flow
analysis was performed by fitting single-phase exponen-
tial decay curve to the mean apoE concentrations at
varying flow rates with the constraint that the plateau
Figure 4 Isoform-dependent differences in apoE levels in the hippocampal ISF. A. ISF samples from the hippocampus of apoE2 KI, apoE3
KI, and apoE4 KI mice were obtained by microdialysis using a constant flow-rate of 1.0 μL/min. ApoE levels were assessed by ELISA and
compared by ANOVA followed by Tukey’s post hoc test. * p<0.05, n=3-6 mice per genotype. Data are presented as mean ± SEM. B. 12.5 ng/mL
of recombinant apoE2, apoE3, or apoE4 was measured by ELISA and compared by ANOVA (p=0.22).
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was set to 0. Percent recovery for each flow rate was cal-
culated using Cx/E * 100, where Cx was the apoE con-
centration at a given flow rate and E was the estimated
apoE concentration at steady-state.
In vivo microdialysis
Mice were anesthetized using 1.5%-2.5% isoflurane, the
head shaved, and an anterior to posterior incision made
along the midline of the head to expose the skull from
several mm anterior of bregma to several mm posterior
of lambda. The mouse was then mounted onto a ma-
nipulator arm-equipped small animal stereotaxic appar-
atus (David Kopf Instruments, Tujunga, CA, USA). The
skull was then leveled to within 0.1 mm at lambda,
bregma, and two points 2.2 mm lateral of midline. A
bore hole (1.0 mm diameter) was then created above the
left hippocampus (bregma -3.1 mm, 2.5 mm lateral, dura
mater -0.6 mm). A second bore hole (0.75 mm) was
placed in the right, anterior quadrant of the skull in
which to place an anchoring bone screw. An AtmosLM
Guide Cannula (PEG-X, Eicom, San Diego, CA, USA)
was then stereotactically inserted into the left hippocam-
pal formation (12° angle, dura mater -1.2 mm). The can-
nula was then secured into place using a binary dental
cement. An AtmosLM Dummy Cannula (PED-X, Eicom,
San Diego, CA, USA) was then inserted into the guide
cannula and secured with a plastic cap nut. The wound
was then closed using surgical adhesive and the animal
placed into a clean cage and provided with access to
food and water ad libitum.
1,000 kDa microdialysis probes (AtmosLM Microdialy-
sis probe, PEP-X-0Y, Eicom, San Diego, CA, USA) were
prepared as described above. Mice were then briefly anes-
thetized with isoflurane and probes were inserted into the
hippocampus through the guide cannula and the mouse
fitted with a plastic collar. Mice were then placed into a
cage designed to allow for free movement without placing
stress on the Teflon tubing or probe apparatus (Raturn
Stand-Alone System, BASi, West Lafayette, IN, USA). The
mice were kept under constant light conditions for the re-
mainder of the experiment. Peristaltic pumps were oper-
ated at maximum speed for two hours to prevent clogging
of the microdialysis membrane. Flow rates were then re-
duced to 1.0 μL/min to measure apoE. Samples were col-
lected bi-hourly using a refrigerated fraction collector
(Univentor 820 Microsampler, SciPro).
ApoE and Aβ ELISAs
The apoE concentration in microdialysis samples were
analyzed by an apoE sandwich ELISA. For human apoE,
a 96-well plate (Nunc) was coated with 500 ng/well HJ
6.2 overnight at 4°C. For murine apoE, 1% milk served
as the capture ligand. The plate was then blocked with
1% milk for 60 min. at 37°C. Microdialysis samples were
diluted with our standard ELISA buffer (0.5% BSA, 0.025%
Tween-20 in PBS, pH 7.4). For human apoE isoforms re-
combinant apoE3 standards were diluted with ELISA buf-
fer and microdialysis perfusion buffer to match the buffer
composition of microdialysis samples. For quantification
of murine apoE, pooled C57BL/6J plasma was used as a
standard. Samples and standards were loaded and incu-
bated overnight at 4°C. Biotinylated mHJ 6.3 or mHJ 6.1
was used as a detection antibody for mouse or human
apoE, respectively. Following a 90 min. incubation at 37°C
with detection antibody, poly-streptavidin-horseradish
peroxidase (HRP) (Thermo Scientific) was applied to the
plate and incubated for 90 min. at room temperature.
ELISAs were then developed using Super Slow ELISA
TMB (Sigma) and read using a Bio-Tek FL-600 plate
reader at 650 nm. Aβx-40 was analyzed by sandwich ELISA
as described previously, using HJ 2 as the capture antibody
and biotinylated HJ 5.1 as the detection antibody [8].
Nondenaturing gradient gel electrophoresis and western
blotting
Microdialysis, CSF, or microdialysis buffer samples were
diluted with Native PAGE sample buffer (Life Technolo-
gies, Carlsbad, CA, USA) and electrophoresed on a 4-20%
Tris-Glycine gel (Life Technologies, Carlsbad, CA, USA)
at 100V for 24 hours at 4°C. A mixture of proteins with
defined hydrated diameters was used for size standards
(Amersham™ HMW Calibration Kit for Native Electro-
phoresis, Cat. # 17-0445-01, GE Healthcare). Proteins
were transferred to a nitrocellulose membrane and probed
with antibodies recognizing goat anti-human apoE (50A-
G1b, 1:200, Academy Biomedical). Membranes were then
washed extensively and probed with a donkey anti-goat
IgG conjugated to HRP (1:5000, sc-2056, Santa Cruz Bio-
technology). Blots were then developed using enhanced
chemiluminescence (Lumigen-TMA6, Lumigen Inc.) and
imaged with a Syngene G-Box (Syngene, Cambridge, UK).
Statistical analysis
Statistical analysis was performed using PRISM version
5.0 (GraphPad). Data are presented as mean ± SEM.
Comparisons between two groups were made using a
two-tailed unpaired t-test. Multiple groups were com-
pared using ANOVA followed by Tukey’s post hoc test.
Statistical significance was assigned to p-values less than
0.05.
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